PMID- 25835612
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1578-1879 (Electronic)
IS  - 0214-9168 (Linking)
VI  - 27
IP  - 3
DP  - 2015 May-Jun
TI  - [Statins diabetogenicity: are all the same? state of art].
PG  - 148-58
LID - S0214-9168(15)00007-8 [pii]
LID - 10.1016/j.arteri.2015.02.001 [doi]
AB  - Statins are the cornerstone of cardiovascular prevention for general population, 
      and in patients with type 2 diabetes mellitus (T2DM). However, statin therapy 
      predisposes to type 2 diabetes, particularly in patients with predisposition to 
      this condition. Some statins have been associated with increases in blood glucose 
      in patients with or without DM2, and others have shown to have neutral effects, 
      varying from one another their glucose or diabetogenic capacity. In many statin 
      trials the incidence of DM2 has not been systematically evaluated and others the 
      power to detect differences between statins is lacking. Evidence highest quality 
      available comes from the meta-analysis of controlled clinical trials. The only 
      controlled clinical trial to evaluate the incidence of new-onset T2DM is the 
      J-PREDICT conducted with pitavastatin in patients with abnormal glucose 
      tolerance. Preliminary results of this study show that pitavastatin is associated 
      with a significant decrease in the incidence of de novo T2DM compared to only 
      modification lifestyle. Therefore, pitavastatin may be an appropriate therapeutic 
      alternative of choice to reduce vascular risk in patients with T2DM or at risk of 
      presenting it.
CI  - Copyright (c) 2015 Sociedad Espanola de Arteriosclerosis. Published by Elsevier 
      Espana. All rights reserved.
FAU - Rius Tarruella, Joan
AU  - Rius Tarruella J
AD  - Medical Affairs Cardiovascular Area, ESTEVE, Barcelona, Espana. Electronic 
      address: 29815jrt@gmail.com.
FAU - Millan Nunez-Cortes, Jesus
AU  - Millan Nunez-Cortes J
AD  - Unidad de Riesgo Cardiovascular y Lipidos, Servicio de Medicina Interna, Hospital 
      General Universitario Gregorio Maranon, Madrid, Espana.
FAU - Pedro-Botet, Juan
AU  - Pedro-Botet J
AD  - Unidad de Riesgo Cardiovascular y Lipidos, Servicio de Endocrinologia y 
      Nutricion, Hospital del Mar, Barcelona, Espana.
FAU - Pinto Sala, Xavier
AU  - Pinto Sala X
AD  - Unidad de Riesgo Cardiovascular y Lipidos, Servicio de Medicina Interna, Hospital 
      Universitario de Bellvitge, Barcelona, Espana.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - La diabetogenicidad de las estatinas:  inverted question markson todas iguales? Estado de la cuestion.
DEP - 20150331
PL  - Spain
TA  - Clin Investig Arterioscler
JT  - Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad 
      Espanola de Arteriosclerosis
JID - 9208512
RN  - 0 (Blood Glucose)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/chemically induced/*epidemiology/prevention & control
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse 
      effects/pharmacology/*therapeutic use
MH  - Incidence
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Diabetes mellitus tipo 2
OT  - Disglicemia
OT  - Dysglycemia
OT  - Enfermedad cardiovascular
OT  - Estatinas
OT  - HbA1c
OT  - Prevencion
OT  - Prevention
OT  - Statins
OT  - Type 2 diabetes mellitus
EDAT- 2015/04/04 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/04/04 06:00
PHST- 2015/02/02 00:00 [received]
PHST- 2015/02/03 00:00 [accepted]
PHST- 2015/04/04 06:00 [entrez]
PHST- 2015/04/04 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0214-9168(15)00007-8 [pii]
AID - 10.1016/j.arteri.2015.02.001 [doi]
PST - ppublish
SO  - Clin Investig Arterioscler. 2015 May-Jun;27(3):148-58. doi: 
      10.1016/j.arteri.2015.02.001. Epub 2015 Mar 31.